Sanhan Huashi granules(SHG)demonstrated therapeutic effects against coronavirus disease 2019(COVID-19)in observational studies.In order to compare the effectiveness and safety of SHG and nirmatrelvir–ritonavir in tre...Sanhan Huashi granules(SHG)demonstrated therapeutic effects against coronavirus disease 2019(COVID-19)in observational studies.In order to compare the effectiveness and safety of SHG and nirmatrelvir–ritonavir in treating adults with mild-to-moderate COVID-19,we conducted a randomized,activecontrolled,open-label,multi-center trial conducted between February and July in 2023.The patients were randomized in a 1:1 ratio to the SHG group and the nirmatrelvir–ritonavir group.A total of 400participants were randomized,among which 200 participants ultimately received SHG and 198 received nirmatrelvir–ritonavir.The primary outcome was time to sustained clinical recovery through day 28.SHG significantly shortened the median time to sustained clinical recovery compared to nirmatrelvir–ritonavir(6.0(95%CI,5.0 to 6.0)vs.8.0(95%CI,6.0 to 9.0)d;P=0.001),particularly for individual symptoms including fever,sore throat,cough and fatigue.No participants in either group died and incidence of severe COVID-19 showed no difference between two groups.Participants who received nirmatrelvir–ritonavir demonstrated a higher rate of virus clearance on day 5 compared to those received SHG(46.4%(95%CI,39.1 to 53.7)vs.65.6%(95%CI,58.3 to 72.4);P<0.001).Most adverse events were mild in both groups.In summary,SHG was superior to nirmatrelvir–ritonavir in shortening the time to sustained clinical recovery in participants with mild-to-moderate COVID-19,despite a lower virus clearance rate observed after 5 d of treatment(Chinese Clinical Trial Registry Identifier:Chi CTR2300067872).展开更多
目的:探讨超声(US)和多层螺旋CT(MSCT)两种检查方法在胃肠道间质瘤(GIST)诊断中的应用价值。方法:选择2015年2月到2017年2月在我院诊治的疑似胃肠道间质瘤患者60例作为研究对象,均进行超声与MSCT检查,判定诊断效果与检查特征。结果:60...目的:探讨超声(US)和多层螺旋CT(MSCT)两种检查方法在胃肠道间质瘤(GIST)诊断中的应用价值。方法:选择2015年2月到2017年2月在我院诊治的疑似胃肠道间质瘤患者60例作为研究对象,均进行超声与MSCT检查,判定诊断效果与检查特征。结果:60例患者经过病理诊断为胃肠道间质瘤35例,诊断为非胃肠道间质瘤25例,胃肠道间质瘤35例中超声表现为低回声32例,伴后方声影27例,内部血流丰富23例,轮廓模糊24例;非胃肠道间质瘤25例中超声表现为低回声8例,伴后方声影6例,内部血流丰富9例,轮廓模糊5例,两组超声特征对比有明显差异(P<0.05)。胃肠道间质瘤患者的CT增强成像参数AT(增强开始时间,Arrival time)、TTP(达峰时间,Time to peak enhancement)值明显低于非胃肠道间质瘤患者(P<0.05),而T1/2(强度半降时间,Time from peak to half)、AUC(曲线下面积,Area under the curve)与EI(增强强度,Enhanced intensity)值明显低于非胃肠道间质瘤患者(P<0.05)。US诊断胃肠道间质瘤的敏感性与特异性分别为80.0%和92.0%,MSCT诊断胃肠道间质瘤的敏感性与特异性分别为97.1%和100.0%,MSCT在胃肠道间质瘤诊断中的敏感性明显高于超声(P<0.05)。结论:US和MSCT检查均可应用于胃肠道间质瘤的诊断,其中MSCT检查效果更佳,具有很好的应用价值,应加以推广。展开更多
基金supported by the Jiangsu Kanion Pharmaceutical Co.,Ltd.and partially supported by the Innovation TeamTalents Cultivation Program of National Administration of Traditional Chinese Medicine(ZYYCXTD-D-202208)。
文摘Sanhan Huashi granules(SHG)demonstrated therapeutic effects against coronavirus disease 2019(COVID-19)in observational studies.In order to compare the effectiveness and safety of SHG and nirmatrelvir–ritonavir in treating adults with mild-to-moderate COVID-19,we conducted a randomized,activecontrolled,open-label,multi-center trial conducted between February and July in 2023.The patients were randomized in a 1:1 ratio to the SHG group and the nirmatrelvir–ritonavir group.A total of 400participants were randomized,among which 200 participants ultimately received SHG and 198 received nirmatrelvir–ritonavir.The primary outcome was time to sustained clinical recovery through day 28.SHG significantly shortened the median time to sustained clinical recovery compared to nirmatrelvir–ritonavir(6.0(95%CI,5.0 to 6.0)vs.8.0(95%CI,6.0 to 9.0)d;P=0.001),particularly for individual symptoms including fever,sore throat,cough and fatigue.No participants in either group died and incidence of severe COVID-19 showed no difference between two groups.Participants who received nirmatrelvir–ritonavir demonstrated a higher rate of virus clearance on day 5 compared to those received SHG(46.4%(95%CI,39.1 to 53.7)vs.65.6%(95%CI,58.3 to 72.4);P<0.001).Most adverse events were mild in both groups.In summary,SHG was superior to nirmatrelvir–ritonavir in shortening the time to sustained clinical recovery in participants with mild-to-moderate COVID-19,despite a lower virus clearance rate observed after 5 d of treatment(Chinese Clinical Trial Registry Identifier:Chi CTR2300067872).
文摘目的:探讨超声(US)和多层螺旋CT(MSCT)两种检查方法在胃肠道间质瘤(GIST)诊断中的应用价值。方法:选择2015年2月到2017年2月在我院诊治的疑似胃肠道间质瘤患者60例作为研究对象,均进行超声与MSCT检查,判定诊断效果与检查特征。结果:60例患者经过病理诊断为胃肠道间质瘤35例,诊断为非胃肠道间质瘤25例,胃肠道间质瘤35例中超声表现为低回声32例,伴后方声影27例,内部血流丰富23例,轮廓模糊24例;非胃肠道间质瘤25例中超声表现为低回声8例,伴后方声影6例,内部血流丰富9例,轮廓模糊5例,两组超声特征对比有明显差异(P<0.05)。胃肠道间质瘤患者的CT增强成像参数AT(增强开始时间,Arrival time)、TTP(达峰时间,Time to peak enhancement)值明显低于非胃肠道间质瘤患者(P<0.05),而T1/2(强度半降时间,Time from peak to half)、AUC(曲线下面积,Area under the curve)与EI(增强强度,Enhanced intensity)值明显低于非胃肠道间质瘤患者(P<0.05)。US诊断胃肠道间质瘤的敏感性与特异性分别为80.0%和92.0%,MSCT诊断胃肠道间质瘤的敏感性与特异性分别为97.1%和100.0%,MSCT在胃肠道间质瘤诊断中的敏感性明显高于超声(P<0.05)。结论:US和MSCT检查均可应用于胃肠道间质瘤的诊断,其中MSCT检查效果更佳,具有很好的应用价值,应加以推广。
